Abstract
The marketed antiepileptic drugs can not solve entirely the problem of seizure in patients suffering from refractory epilepsies. Therefore, new anticonvulsant compounds structurally and pharmacologically different of the currently prescribed drugs are needed. Carbonic anhydrase (CA) inhibitors are known to act as anticonvulsant since several decades while the link between CA and seizure is not straightforward. However, the recent discovery that several CA isozymes are expressed in brain and the better knowledge of their physiological/ pathological role, lead to the emergence of new CA inhibitors with anticonvulsant effect including: analogues of acetazolamide, analogues of topiramate, aromatic or heterocyclic sulfonamides incorporating valproyl or adamantyl moieties. Different strategies are developed for the design of new more selective CA inhibitors with anticonvulsant properties.
Keywords: sulfamate, sulfamide, sulfonamide, drug design, carbonic anhydrase, antiepileptic drugs, Seizures
Current Pharmaceutical Design
Title: Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action
Volume: 14 Issue: 7
Author(s): Bernard Masereel, Anne Thiry, Jean-Michel Dogne and Claudiu T. Supuran
Affiliation:
Keywords: sulfamate, sulfamide, sulfonamide, drug design, carbonic anhydrase, antiepileptic drugs, Seizures
Abstract: The marketed antiepileptic drugs can not solve entirely the problem of seizure in patients suffering from refractory epilepsies. Therefore, new anticonvulsant compounds structurally and pharmacologically different of the currently prescribed drugs are needed. Carbonic anhydrase (CA) inhibitors are known to act as anticonvulsant since several decades while the link between CA and seizure is not straightforward. However, the recent discovery that several CA isozymes are expressed in brain and the better knowledge of their physiological/ pathological role, lead to the emergence of new CA inhibitors with anticonvulsant effect including: analogues of acetazolamide, analogues of topiramate, aromatic or heterocyclic sulfonamides incorporating valproyl or adamantyl moieties. Different strategies are developed for the design of new more selective CA inhibitors with anticonvulsant properties.
Export Options
About this article
Cite this article as:
Masereel Bernard, Thiry Anne, Dogne Jean-Michel and Supuran T. Claudiu, Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action, Current Pharmaceutical Design 2008; 14 (7) . https://dx.doi.org/10.2174/138161208783877956
DOI https://dx.doi.org/10.2174/138161208783877956 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Activity-Dependent Release of Adenosine: A Critical Re-Evaluation of Mechanism
Current Neuropharmacology Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Calixarene: A Versatile Material for Drug Design and Applications
Current Pharmaceutical Design ABC Pumps and Their Role in Active Drug Transport
Current Topics in Medicinal Chemistry Theory and Application of Microdialysis in Pharmacokinetic Studies
Current Drug Metabolism Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets To Analyze the Amelioration of Phenobarbital Induced Oxidative Stress by Erucin, as Indicated by Biochemical and Histological Alterations
Anti-Cancer Agents in Medicinal Chemistry Genome-wide Membrane Protein Structure Prediction
Current Genomics Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry Mechanisms and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Suicidality and Cannabidiol: Opportunities and Challenges
Current Neuropharmacology Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice
CNS & Neurological Disorders - Drug Targets Synthesis, Molecular Docking and Evaluation of 3-{4-[2-amino-4-(substitutedphenyl)-2H-[1, 3] oxazin/thiazin-6-yl} 2-phenyl-3H-quinazolin-4-one Derivatives for their Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry New Proposals for Testing Drugs with IKr-Blocking Activity to Determine Their Teratogenic Potential
Current Pharmaceutical Design Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety